[go: up one dir, main page]

ES2165361T3 - Utilizacion de conjugados de bismuto-213 para el tratamiento de micrometastasis. - Google Patents

Utilizacion de conjugados de bismuto-213 para el tratamiento de micrometastasis.

Info

Publication number
ES2165361T3
ES2165361T3 ES93202174T ES93202174T ES2165361T3 ES 2165361 T3 ES2165361 T3 ES 2165361T3 ES 93202174 T ES93202174 T ES 93202174T ES 93202174 T ES93202174 T ES 93202174T ES 2165361 T3 ES2165361 T3 ES 2165361T3
Authority
ES
Spain
Prior art keywords
conjugates
therapy
bismuto
micrometastasis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93202174T
Other languages
English (en)
Inventor
Maurits Willem Geerlings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2165361T3 publication Critical patent/ES2165361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Massaging Devices (AREA)
  • Tents Or Canopies (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL CAMPO DE LA TERAPIA DIRIGIDA LOCAL. MAS ESPECIFICAMENTE SE REFIERE A LA RADIO TERAPIA DIRIGIDA LOCAL. PROPORCIONA UN METODO PARA LA PRODUCCION DE CONJUGADOS RADIOINMUNES PARA TERAPIA RADIOINMUNE. EL METODO, LOS CONJUGADOS Y EL APARATO PUEDEN SER PUESTOS EN PRACTICA SIN LA NECESIDAD DE INSTALACIONES DE ESTANCAS AL AIRE Y/O PROTECCION RADIOACTIVA. SIN ESTAS RESTRICCIONES LA INVENCION PROPORCIONA UN MEDIO SENCILLO Y EFICAZ DE TERAPIA EN LA CABECERA DE UN PACIENTE.
ES93202174T 1992-07-27 1993-07-22 Utilizacion de conjugados de bismuto-213 para el tratamiento de micrometastasis. Expired - Lifetime ES2165361T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92202301 1992-07-27
EP93200388 1993-02-11

Publications (1)

Publication Number Publication Date
ES2165361T3 true ES2165361T3 (es) 2002-03-16

Family

ID=26131590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93202174T Expired - Lifetime ES2165361T3 (es) 1992-07-27 1993-07-22 Utilizacion de conjugados de bismuto-213 para el tratamiento de micrometastasis.

Country Status (15)

Country Link
US (2) US5641471C1 (es)
EP (1) EP0585986B1 (es)
JP (1) JP3959431B2 (es)
KR (1) KR100304155B1 (es)
AT (1) ATE206622T1 (es)
AU (1) AU676162B2 (es)
CA (1) CA2100709C (es)
DE (1) DE69330899T2 (es)
DK (1) DK0585986T3 (es)
ES (1) ES2165361T3 (es)
FI (1) FI118676B (es)
MX (1) MX9304499A (es)
NO (1) NO312009B1 (es)
NZ (1) NZ248235A (es)
PT (1) PT585986E (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
ES2183904T3 (es) * 1996-11-15 2003-04-01 Euratom Metodo extracorporeo para el tratamiento de celulas sanguineas.
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
US5854968A (en) * 1997-06-09 1998-12-29 Arch Development Corporation Process and apparatus for the production of BI-213 cations
US6603127B1 (en) * 1998-03-30 2003-08-05 Sloan-Kettering Institute For Cancer Research Bismuth-213 generator and uses thereof
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
ATE381345T1 (de) * 1998-05-26 2008-01-15 Sloan Kettering Inst Cancer Alpha-emittierende konstrukte sowie deren verwendung
ATE246395T1 (de) 1998-06-22 2003-08-15 Europ Economic Community Verfahren und vorrichtung zur erzeugung von bi- 213 für menschliche therapeutische verwendung
JP2004510683A (ja) * 1999-06-07 2004-04-08 センター・フォー・モレキュラー・メディシン・アンド・イムノロジー 放射免疫療法において断片に付着されるα線エミッタまたはβ線エミッタ
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
WO2004001767A1 (en) * 2002-06-21 2003-12-31 Lynntech, Inc. Ion exchange materials for use in a bi-213 generator
EP1479399A1 (en) * 2003-05-22 2004-11-24 European Atomic Energy Community (Euratom) Method of loading a radioelement generator with mother radionuclide
US20050105666A1 (en) * 2003-09-15 2005-05-19 Saed Mirzadeh Production of thorium-229
CA2768658C (en) 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
EP3302560A4 (en) 2015-06-05 2019-01-09 Panacea Pharmaceuticals, Inc. RADIOIMAGING AND RADIATION THERAPY OF CANCER USING ANTIBODIES AGAINST HAAH
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) * 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) * 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
CA1225930A (en) * 1982-06-07 1987-08-25 Otto A. Gansow Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) * 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
AU2068588A (en) * 1987-08-12 1989-02-16 Immunomedics Inc. Preparation of radiolabeled conjugates
US4833329A (en) * 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4871352A (en) * 1987-12-07 1989-10-03 Controlled Release Technologies, Inc. Self-regulated therapeutic agent delivery system and method
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
JPH0720989B2 (ja) * 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
DK0429624T3 (da) * 1989-06-19 1994-05-30 Akzo Nobel Nv Radioimmunterapi under anvendelse af alfa-partikelemission
EP0484460B1 (en) * 1989-07-12 1996-01-17 Mallinckrodt Medical, Inc. Method for preparing radiodiagnostic gaseous radionuclide and apparatus
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) * 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
NZ248235A (en) 1995-04-27
NO932687L (no) 1994-01-28
AU4215493A (en) 1994-02-03
KR940005295A (ko) 1994-03-21
US5641471C1 (en) 2001-05-15
CA2100709C (en) 2004-03-16
JPH06157350A (ja) 1994-06-03
DE69330899D1 (de) 2001-11-15
MX9304499A (es) 1994-04-29
AU676162B2 (en) 1997-03-06
US5641471A (en) 1997-06-24
JP3959431B2 (ja) 2007-08-15
NO312009B1 (no) 2002-03-04
KR100304155B1 (ko) 2001-11-22
FI933350L (fi) 1994-01-28
EP0585986B1 (en) 2001-10-10
DE69330899T2 (de) 2002-04-25
CA2100709A1 (en) 1994-01-28
EP0585986A1 (en) 1994-03-09
PT585986E (pt) 2002-03-28
DK0585986T3 (da) 2002-01-14
FI933350A0 (fi) 1993-07-26
ATE206622T1 (de) 2001-10-15
US6127527A (en) 2000-10-03
FI118676B (fi) 2008-02-15
NO932687D0 (no) 1993-07-26

Similar Documents

Publication Publication Date Title
ES2165361T3 (es) Utilizacion de conjugados de bismuto-213 para el tratamiento de micrometastasis.
PL349216A1 (en) Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
NO20032027D0 (no) Effektive antitumorbehandlinger
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
DK1140181T3 (da) Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
ITMI20000630A0 (it) Impiego del resveratrolo per il trattamento di eczema disquamativo anche e psoriasi
SE9802208D0 (sv) Novel compounds
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
DK0588873T3 (da) Behandling af levercancer
HK1028545A1 (en) Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
DE69217221D1 (de) Hydrochinonderivate und diese enthaltende Antioxydantien sowie Tumorinhibitoren
UA31156A (uk) Спосіб лікування пневмоентеритів телят
RU94006564A (ru) Устройство для светолечения
UY26519A1 (es) " tratamiento del dolor".
IT7821089A0 (it) Decodificatore per la tutela del apparecchio codificatore e segreto delle comunicazioni.
UA8280A (uk) Спосіб лікування псоріазу
IT8011954V0 (it) Manipolo per apparecchi terapeutici e di trattamenti estetici
UA23040C2 (uk) Пристрій для імпульсhої електромагhітhої терапії
ITFI930069A0 (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 585986

Country of ref document: ES